검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Darzalex (daratumumab) | Humira (adalimumab) | Cosentyx (secukinumab) | Stelara (ustekinumab) |
Overview Company | Merck | Janssen | AbbVie | Novartis | Janssen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | CD38 | TNF-α | IL-17A | IL-12 / IL-23 (p40) |
Overview Indication | Multiple solid tumors | Multiple myeloma | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, ankylosing spondylitis | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
MoA Mechanism | PD-1 blockade → T-cell reinvigoration | CD38 targeting, Fc effector function, immunomodulation | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | targeting IL-12 family signaling |
MoA Biomarker | PD-L1, MSI-H, TMB | CD38 expression on plasma cells | biomarkers to support personalized treatment strategies | biomarkers and optimize therapeutic strategies | biomarkers but require external validation in independent cohorts |
PK/PD Half-life | 3 h | 0.5 h | — | 31 h | 19 h |
PK/PD Species | Mouse, Rat | Mouse | Rat, xenografts, which corroborat | Mouse, Human | Cynomolgus monkey, NHP, Marmoset |
PK/PD Animal (cat.) | Mouse, Rat, In vitro | Mouse | Rat | Human, Mouse | Human, NHP |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Macaque, Mouse, Rat | Mouse | Rat, xenografts, which corroborat | Mouse, Human | Cynomolgus monkey, NHP, Mouse, Marmoset |
Toxicology Animal (cat.) | — | Unknown | Unknown | Mouse | Mouse, NHP |
Toxicology Major finding | Immune-related AEs | Hepatotoxicity Hepatotoxicity includes alanine aminotransferase increased, aspartate aminot | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | — | — |
Toxicology CRS | N/A | — | — | — | — |
Clinical Primary efficacy | ORR 38% | ORR 80% | ORR 98.85% | ORR 78.1% | ORR 75% |
Clinical PASI75 | — | — | — | — | 67% |
Clinical ORR | 38% | >80% in combo regimens | 98.85% | 78.10% | PASI75 ~67% (PsO pivotal) |
Clinical Result source | ClinicalTrials.gov NCT02444741 | POLLUX/CASTOR | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT04732117 | PHOENIX |
Clinical Data Tier / Score | C · 80 | S · 94 | A · 92 | B · 91 | C · 91 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Dose / schedule | q3w or q6w | — | — | — | — |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Darzalex (daratumumab) | Humira (adalimumab) | Cosentyx (secukinumab) | Stelara (ustekinumab) |
Overview Company | Merck | Janssen | AbbVie | Novartis | Janssen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | CD38 | TNF-α | IL-17A | IL-12 / IL-23 (p40) |
Overview Indication | Multiple solid tumors | Multiple myeloma | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, ankylosing spondylitis | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
MoA Mechanism | PD-1 blockade → T-cell reinvigoration | CD38 targeting, Fc effector function, immunomodulation | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | targeting IL-12 family signaling |
MoA Biomarker | PD-L1, MSI-H, TMB | CD38 expression on plasma cells | biomarkers to support personalized treatment strategies | biomarkers and optimize therapeutic strategies | biomarkers but require external validation in independent cohorts |
PK/PD Half-life | 3 h | 0.5 h | — | 31 h | 19 h |
PK/PD Species | Mouse, Rat | Mouse | Rat, xenografts, which corroborat | Mouse, Human | Cynomolgus monkey, NHP, Marmoset |
PK/PD Animal (cat.) | Mouse, Rat, In vitro | Mouse | Rat | Human, Mouse | Human, NHP |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Macaque, Mouse, Rat | Mouse | Rat, xenografts, which corroborat | Mouse, Human | Cynomolgus monkey, NHP, Mouse, Marmoset |
Toxicology Animal (cat.) | — | Unknown | Unknown | Mouse | Mouse, NHP |
Toxicology Major finding | Immune-related AEs | Hepatotoxicity Hepatotoxicity includes alanine aminotransferase increased, aspartate aminot | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | — | — |
Toxicology CRS | N/A | — | — | — | — |
Clinical Primary efficacy | ORR 38% | ORR 80% | ORR 98.85% | ORR 78.1% | ORR 75% |
Clinical PASI75 | — | — | — | — | 67% |
Clinical ORR | 38% | >80% in combo regimens | 98.85% | 78.10% | PASI75 ~67% (PsO pivotal) |
Clinical Result source | ClinicalTrials.gov NCT02444741 | POLLUX/CASTOR | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT04732117 | PHOENIX |
Clinical Data Tier / Score | C · 80 | S · 94 | A · 92 | B · 91 | C · 91 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Dose / schedule | q3w or q6w | — | — | — | — |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교